Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co. Ltd (323990) - Total Liabilities
Latest total liabilities as of September 2025: ₩5.28 Billion KRW
Based on the latest financial reports, Vaxcell-Bio Therapeutics Co. Ltd (323990) has total liabilities worth ₩5.28 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaxcell-Bio Therapeutics Co. Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Vaxcell-Bio Therapeutics Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaxcell-Bio Therapeutics Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Vaxcell-Bio Therapeutics Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AROAF
PINK:AROAF
|
USA | $14.35 Million |
|
Namsun Alumini
KO:008350
|
Korea | ₩144.33 Billion |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
India | ₹2.91 Billion |
|
Talga Group Ltd
PINK:TLGRF
|
USA | $6.61 Million |
|
Beijing Liven Technology Co. Ltd.
SHE:001259
|
China | CN¥120.05 Million |
|
Tornado Global Hydrovacs Ltd
V:TGH
|
Canada | CA$64.04 Million |
|
Bliss GVS Pharma Limited
NSE:BLISSGVS
|
India | ₹2.32 Billion |
|
ReposiTrak
NASDAQ:TRAK
|
USA | $5.44 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Vaxcell-Bio Therapeutics Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxcell-Bio Therapeutics Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxcell-Bio Therapeutics Co. Ltd (2018–2024)
The table below shows the annual total liabilities of Vaxcell-Bio Therapeutics Co. Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩4.95 Billion | +232.89% |
| 2023-12-31 | ₩1.49 Billion | +77.91% |
| 2022-12-31 | ₩835.78 Million | -30.12% |
| 2021-12-31 | ₩1.20 Billion | +44.08% |
| 2020-12-31 | ₩830.10 Million | -13.93% |
| 2019-12-31 | ₩964.46 Million | -96.06% |
| 2018-12-31 | ₩24.45 Billion | -- |